Study wrapper · #1370
Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.
Editor's note
This is a post-hoc analysis of a registered randomized trial, so the endothelial markers were not the primary endpoint and the study was likely underpowered for them, as the authors acknowledge. The results cut both ways: E-Selectin moved in a favorable direction on semaglutide while VCAM-1 moved unfavorably, and the reactive hyperaemic index improved only against baseline, not placebo. With 120 participants split across four arms, this is best read as mechanistic signal-generation rather than an answer to how semaglutide lowers cardiovascular risk. The heterogeneous marker responses are the genuinely interesting finding.
Plain-language abstract
In a 32-week randomized trial of 120 adults with type 2 diabetes, researchers checked whether semaglutide or empagliflozin changed markers of blood-vessel lining health. Semaglutide lowered one inflammation-linked marker (E-Selectin) versus placebo, but another marker (VCAM-1) actually rose, and the main measure of vessel function did not clearly beat placebo.